Cervical Adenosquamous Carcinoma
Associated Genetic Biomarkers
NCI Definition: An uncommon carcinoma arising from the cervix. It is composed of malignant glandular epithelial cells and malignant squamous epithelial cells. 
Cervical adenosquamous carcinomas most frequently harbor alterations in STK11, PTEN, PIK3CA, PIK3R1, and KRAS .
PIK3CA Mutation, PTEN Mutation, PIK3CA E545K, PIK3CA Codon 545 Missense, and STK11 Mutation are the most common alterations in cervical adenosquamous carcinoma .
There are 24 clinical trials for cervical adenosquamous carcinoma, of which 22 are open and 2 are completed or closed. Of the trials that contain cervical adenosquamous carcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 4 are phase 1/phase 2 (4 open), 8 are phase 2 (8 open), 1 is phase 2/phase 3 (1 open), and 7 are phase 3 (6 open).
PD-L1, CDKN2A, and HPV are the most frequent gene inclusion criteria for cervical adenosquamous carcinoma clinical trials .
Pembrolizumab, bevacizumab, and paclitaxel are the most common interventions in cervical adenosquamous carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.